Alivus Life Sciences Announces 15th AGM on Sep 8, 2026, with Dividend Payout
Alivus Life Sciences will hold its 15th AGM on September 8, 2026, to approve a final dividend of ₹5.00 per equity share for FY26. The record date for dividend entitlement is September 1, 2026. Dividend payments are expected on or after September 11, 2026.
The AGM and dividend declaration are important events for shareholders, impacting their investment decisions and returns. The record date and payment date provide crucial information for shareholders.
The announcement is a routine corporate event, the AGM, and dividend declaration. While a dividend is positive, the overall sentiment is neutral as it is a standard procedure.
Alivus Life Sciences Limited (formerly Glenmark Life Sciences Limited) has announced its Fifteenth (15th) Annual General Meeting (AGM) will be held on Tuesday, September 8, 2026, at 03:00 pm (IST) through Video Conferencing (VC) or Other Audio-Visual Means (OAVM). The Board of Directors had previously recommended a final dividend of ₹5.00 per equity share of ₹2 each for the financial year ended March 31, 2026. This dividend requires approval from the shareholders at the AGM.
The company has fixed Tuesday, September 1, 2026, as the 'Record Date' to determine the entitlement of members to receive the dividend. If approved at the AGM, the dividend payment, after tax deduction, is scheduled to be made on or after Friday, September 11, 2026. This payment will be made to beneficial owners in dematerialized form based on data as of September 1, 2026, and to members holding shares in physical form after processing valid transmission or transposition requests lodged by the same date. The announcement will also be posted on the company's website, www.alivus.com.
What to do with a filing like this
Alivus Life Sciences Limited filed this with the NSE as a statutory disclosure, categorised under agm. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Alivus Life Sciences Limited. Read the original for the full detail.